Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02408276 · ClinicalTrials.gov registry record

Longitudinal Evaluation of Hip Cartilage Degeneration: FAI

A clinical trial, sponsored by Hospital for Special Surgery, New York.

Completed
Registry status
130
Enrollment target

NCT02408276 is a clinical trial that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 130 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02408276 has completed, sponsored by Hospital for Special Surgery, New York.

COMPLETED
Registry status
130 participants
Enrollment target

Study Summary

Femoroacetabular impingement (FAI) is one of the most common mechanisms leading to the development of early cartilage and labral damage in the non-dysplastic hip. Anatomic abnormalities of the proximal femur and/or acetabulum result in repetitive injury during dynamic hip motion, leading to abnormal regional loading of the femoral head-neck junction against the acetabular rim. The resulting damage to the cartilage, labrum, and surrounding capsular structures predispose the patient to developing hip pain and early osteoarthritic changes. Clinically, patients with FAI are a heterogeneous group, with a wide array of presentation from pain to instability that may or may not be related to activity. To date no studies have identified specific prognostic indicators associated with successful surgical treatment of FAI, leaving surgeons without adequate criteria to determine which patients are best suited for arthroscopy. The investigators propose to address this critical knowledge gap by identifying the patient characteristics and morphological features of the hip that are associated with the optimal clinical outcomes in patients undergoing hip arthroscopy or non-operative management for treatment of suspected FAI in order to establish a treatment algorithm for FAI patients.

Interventions

  • OTHER dGEMERIC MRI technique

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2014-12
Est. Completion 2025-12-18

What the Registry Record Tells You About NCT02408276

The ClinicalTrials.gov registry entry for NCT02408276 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which dGEMERIC MRI technique is the first listed.

NCT02408276 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02408276 about?

NCT02408276 is a clinical study titled "Longitudinal Evaluation of Hip Cartilage Degeneration: FAI". Femoroacetabular impingement (FAI) is one of the most common mechanisms leading to the development of early cartilage and labral damage in the non-dysplastic hip. Anatomic abnormalities of the proximal femur and/or acetabulum result in repetitive injury during dynamic hip motion, leading to abnormal...

What is the current status of trial NCT02408276?

This trial is currently completed. The enrollment target is 130 participants. The study started on 2014-12. Estimated completion is 2025-12-18.

What interventions are being tested in trial NCT02408276?

The interventions under investigation include: dGEMERIC MRI technique (OTHER).

Who is sponsoring clinical trial NCT02408276?

This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.